Fructose-functionalized core-cross-linked star glycopolymers enable GLUT-mediated targeted PDT and provide a stable and selective nanoplatform for breast cancer therapy.
Abstract
Porphyrin photosensitizers for photodynamic therapy (PDT) are often limited by poor solubility, aggregation, and insufficient tumor selectivity. Here, fructose-decorated porphyrin core-cross-linked star glycopolymers (CGs) were constructed via an arm-first ATRP strategy, affording a covalently stabilized porphyrin core and a fructose-rich corona. After deprotection, the CGs were readily dispersible in water and retained characteristic photophysical properties with efficient singlet oxygen generation. The optimized formulation, C5G, showed higher uptake in MCF-7 cells than in HepG2 cells, and this uptake was reduced by fructose-containing competitors and a broad GLUT inhibitor. Under light irradiation, C5G induced strong intracellular ROS production and pronounced apoptosis-dominated phototoxicity with negligible dark toxicity. Transcriptomic analysis revealed coordinated regulation of stress-response and cell-death associated pathways following PDT. These results demonstrate that fructose-functionalized core-cross-linked star glycopolymers enable GLUT-mediated targeted PDT and provide a stable and selective nanoplatform for breast cancer therapy.
Porphyrin-based photosensitizers (PSs) are among the most widely explored agents for photodynamic therapy (PDT), yet their clinical translation is severely limited by poor biocompatibility, aggregation-induced quenching, insufficient tumor selectivity, and the intrinsic reactive oxygen species (ROS) resistance of cance...
Yi-Hui Ai, Chong-Zhi Wu, Zhi-Yao Li et al.· Small· 0 citations
Two donor–π–acceptor type photosensitizers, TC1 and TC2, are designed by bridging electron-rich carbazole with electron-withdrawing tricyanofuran (TCF) via thiophene or EDOT moieties as promising targeted theranostic agents for NIR imaging and PDT of breast cancer.
Yu Tang, Zhuo Song, Lu-Lu Sun et al.· RSC Advances· 0 citations
Hepatocellular carcinoma (HCC) remains therapeutically challenging. Sorafenib, the standard first-line therapy for advanced HCC, suffers from poor aqueous solubility, non-specific biodistribution, dose-limiting toxicities, and the emergence of mitochondrial-mediated resistance. Here, we engineered a dual-targeted den...
Vikrantvir Jain, A. I. Dar, Ananya Biswas et al.· Biomacromolecules· 0 citations
Photothermal therapy (PTT) offers the advantages of noninvasiveness and high selectivity, while chemotherapy shows potent antitumor activity. However, their standalone applications are limited by insufficient photothermal ablation efficacy and chemotherapeutic resistance, respectively. To address these challenges, we...
Yu Jiang, Chen Guo, Zhen-Kun Sun et al.· Molecular Pharmaceutics· 0 citations
Lysosomes play a crucial role in ferroptosis, presenting a dual opportunity for disease diagnosis and targeted cancer therapy. However, existing lysosomal probes generally lack the photosensitizing capabilities necessary to induce ferroptosis. Herein, we report the development of a novel series of benzimidazole−couma...
Gan Li, Zhuo-Liang Zhou, Ming-Hao Hu· Analytical Chemistry· 0 citations
Photodynamic therapy (PDT), as a promising anticancer strategy, has attracted much attention due to the advantages of non-invasiveness, temporal-spatial selectivity, and low tendency to induce drug resistance. However, the clinical translation of PDT faces severe challenges, owing to the oxygen-demanding nature of ROS...